van Baal P - Search Results

1

The economics of improving global infectious disease surveillance.

de Vries L, Koopmans M, Morton A, van Baal P. de Vries L, et al. Among authors: van baal p. BMJ Glob Health. 2021 Sep;6(9):e006597. doi: 10.1136/bmjgh-2021-006597. BMJ Glob Health. 2021. PMID: 34475025 Free PMC article. No abstract available.

2

Morton A, Adler AI, Bell D, Briggs A, Brouwer W, Claxton K, Craig N, Fischer A, McGregor P, van Baal P. Morton A, et al. Among authors: van baal p. Health Econ. 2016 Aug;25(8):933-8. doi: 10.1002/hec.3366. Health Econ. 2016. PMID: 27374115 Free article.

3

Developing a framework to assess the costeffectiveness of COMPARE - a global platform for the exchange of sequence-based pathogen data.

Alleweldt F, Kara S, Osinski A, Van Baal P, Kellerborg K, Aarestrup FM, Koopmans M. Alleweldt F, et al. Among authors: van baal p. Rev Sci Tech. 2017 Apr;36(1):311-322. doi: 10.20506/rst.36.1.2631. Rev Sci Tech. 2017. PMID: 28926006 Free article. Review.

4

Should cost effectiveness analyses for NICE always consider future unrelated medical costs?

van Baal P, Morton A, Brouwer W, Meltzer D, Davis S. van Baal P, et al. BMJ. 2017 Nov 10;359:j5096. doi: 10.1136/bmj.j5096. BMJ. 2017. PMID: 29127081 Free article. No abstract available.

5

Health care input constraints and cost effectiveness analysis decision rules.

van Baal P, Morton A, Severens JL. van Baal P, et al. Soc Sci Med. 2018 Mar;200:59-64. doi: 10.1016/j.socscimed.2018.01.026. Epub 2018 Jan 28. Soc Sci Med. 2018. PMID: 29421472 Free PMC article.

6

Future unrelated medical costs need to be considered in cost effectiveness analysis.

van Baal P, Morton A, Meltzer D, Brouwer W. van Baal P, et al. Eur J Health Econ. 2019 Feb;20(1):1-5. doi: 10.1007/s10198-018-0976-0. Eur J Health Econ. 2019. PMID: 29671143 Free article.

7

Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

de Vries LM, van Baal PHM, Brouwer WBF. de Vries LM, et al. Pharmacoeconomics. 2019 Feb;37(2):119-130. doi: 10.1007/s40273-018-0749-8. Pharmacoeconomics. 2019. PMID: 30474803 Free PMC article.

8

Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.

Kellerborg K, Brouwer W, van Baal P. Kellerborg K, et al. Among authors: van baal p. Eur J Health Econ. 2020 Dec;21(9):1329-1350. doi: 10.1007/s10198-020-01218-4. Epub 2020 Aug 13. Eur J Health Econ. 2020. PMID: 32789780 Free PMC article. Review.

9

Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0.

Kellerborg K, Perry-Duxbury M, de Vries L, van Baal P. Kellerborg K, et al. Among authors: van baal p. Value Health. 2020 Nov;23(11):1453-1461. doi: 10.1016/j.jval.2020.07.004. Epub 2020 Oct 2. Value Health. 2020. PMID: 33127016 Free article.

10

Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.

de Vries LM, Kellerborg KM, Brouwer WBF, van Baal PHM. de Vries LM, et al. Among authors: van baal phm. Vaccine. 2021 Jun 29;39(29):3834-3843. doi: 10.1016/j.vaccine.2021.05.091. Epub 2021 Jun 9. Vaccine. 2021. PMID: 34116878 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters